HPV E6, E6AP and cervical cancer
2008
HPV E6, E6AP and cervical cancer
publication
Evidence: moderate
Author Information
Author(s): Beaudenon Sylvie, Huibregtse Jon M
Primary Institution: Asuragen, Inc.
Hypothesis
How do HPV E6 and E6AP contribute to cervical cancer development?
Conclusion
The study suggests that targeting the interaction between HPV E6 and E6AP could provide new therapeutic strategies for cervical cancer.
Supporting Evidence
- HPV E6 is expressed in virtually all HPV-positive cervical cancers.
- E6AP alters the substrate specificity of the ubiquitin ligase, leading to p53 degradation.
- Transgenic mouse models have shown that E6 contributes to skin cancer development.
- Targeting the E6/E6AP interaction may lead to new cancer therapies.
Takeaway
HPV E6 helps cancer grow by breaking down a protein that stops tumors, and scientists are looking for ways to stop this from happening.
Methodology
The study involved biochemical characterization of the HPV E6 and E6AP proteins and their interactions.
Limitations
The natural targets of E6AP are poorly characterized, which complicates understanding its full role in cancer.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website